LOS ANGELES, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Tandem Diabetes Care, Inc. (“Tandem” or the “Company”) (NASDAQ: TNDM) on behalf of investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON TANDEM DIABETES CARE, INC. (TNDM), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.   What Is The Investigation About? On August 7, 2025, Tandem disclosed that a m ...

Accessibility StatementSkip Navigation GALWAY, Ireland, Sept. 29, 2025 /PRNewswire/ -- Medtronic plc (the "Company") (NYSE: MDT) announced today that its wholly-owned indirect subsidiary, Medtronic, Inc., has closed a registered public offering (the "Offering") of €750,000,000 principal amount of 2.950% senior notes due 2030 and €750,000,000 principal amount of 4.200% senior notes due 2045 (collectively, the "Notes"). All of Medtronic, Inc.'s obligations under the Notes are fully and unconditionally guarant ...

Core Insights - Medtronic plans to separate its Diabetes business into a new standalone company, enhancing focus on high-margin growth areas and simplifying its portfolio [1][2][3] - The separation is expected to be completed within 18 months, primarily through an initial public offering (IPO) and subsequent split-off, aimed at unlocking value for shareholders [2][9] - The Diabetes business currently represents 8% of Medtronic's revenue and 4% of its segment operating profit for fiscal year 2025, with anticipated improvements in gross and operating margins post-separation [7] Medtronic's Strategy - Post-separation, Medtronic will concentrate on innovation-driven growth and category leadership in healthcare systems, leveraging its core competencies [3][6] - The company is focusing on its highest profitable growth drivers, including advancements in its innovation pipeline and product launches [3][4] - Medtronic expects durable, mid-single digit or higher organic revenue growth and enhanced earnings leverage following the separation [3] New Diabetes Company - The New Diabetes Company will be a leading direct-to-consumer business, uniquely positioned to offer a complete ecosystem for intensive insulin management [4][5] - The separation will allow for more focused investment in the New Diabetes Company's pipeline and manufacturing capabilities, driving margin expansion over time [4][7] - Que Dallara, the current EVP and president of Medtronic Diabetes, will become the CEO of the New Diabetes Company [5] Financial Implications - The separation is projected to improve Medtronic's adjusted gross margin by approximately 50 basis points and adjusted operating margins by about 100 basis points, with immediate accretion to adjusted EPS [7][8] - The transaction is expected to be tax-free for Medtronic shareholders for U.S. federal income tax purposes, facilitating share retirements without cash reduction [8][9] - Medtronic aims to maintain its dividend per share unchanged pre- and post-transaction, ensuring continued shareholder returns [7]